Effective January 5, 2021
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
Author: Jonathan McLellan
CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status
Effective December 2, 2020
CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts
Effective November 18, 2020
CVRx’s BAROSTIM NEO™ Receives CMS NTAP
Effective October 1, 2020